# Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

> **NCT06155279** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 41 (actual)

## Conditions studied

- Pleural Mesothelioma

## Interventions

- **DRUG:** Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab

## Key facts

- **NCT ID:** NCT06155279
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2025-12-22
- **Final completion:** 2027-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155279, "Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT06155279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*